Vedolizumab for the treatment of ulcerative colitis

Expert Opinion on Biological Therapy

Volumn 16, Issue 1, 2016, Pages 129-135

  Shahidi, Neal ^a   Bressler, Brian ^a   Panaccione, Remo ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

IBD; inflammatory bowel disease; integrins; UC

Indexed keywords

GASTROINTESTINAL AGENT; INTEGRIN; INTEGRIN ALPHA4BETA7; MONOCLONAL ANTIBODY; VEDOLIZUMAB;

ANIMAL; COLITIS, ULCERATIVE; CROHN DISEASE; HUMAN; IMMUNOLOGY; METABOLISM; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC);

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COLITIS, ULCERATIVE; CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS; INTEGRINS;

EID: 84955743533     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2016.1121231     Document Type: Review

References (43)

1. Bernstein CN, Ng SC, Lakatos PL., et al. A review of mortality and surgery in ulcerative colitis: milestones of the seriousness of the disease. Inflamm Bowel Dis. 2013; 19: 2001-2010
2. Rocchi A, Benchimol EI, Bernstein CN., et al. Inflammatory bowel disease: a Canadian burden of illness review. Can J Gastroenterol. 2012; 26: 811-817
3. Singh S, Al-Darmaki A, Frolkis AD., et al. Post-operative mortality among patients with inflammatory bowel diseases: A systematic review and meta-analysis of population-based studies. Gastroenterology. 2015;149;928-937
4. Seksik P, Sokol H, Lepage P., et al. Review article: the role of bacteria in onset and perpetuation of inflammatory bowel disease. Aliment Pharmacol Ther. 2006; 24: 11-18
5. Mosli MH, Rivera-Nieves J, Feagan BG. T-cell trafficking and anti-adhesion strategies in inflammatory bowel disease: current and future prospects. Drug. 2014; 74: 297-311
6. Lennard-Jones JE, Misiewicz JJ, Connell AM., et al. Prednisone as maintenance treatment for ulcerative colitis in remission. Lancet. 1965; 1: 188-189
7. Truelove SC, Witts LJ. Cortisone and corticotrophin in ulcerative colitis. Br Med J. 1959; 1: 387-394
8. Ford AC, Bernstein CN, Khan KJ., et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011; 106: 590-599
9. Bjarnason I, Macpherson A, Mackintosh C., et al. Reduced bone density in patients with inflammatory bowel disease. Gut. 1997; 40: 228-233
10. Khan KJ, Dubinsky MC, Ford AC., et al. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011; 106: 630-642
11. Timmer A, McDonald JW, Tsoulis DJ., et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012; 9: CD000478
12. Kotlyar DS, Osterman MT, Diamond RH., et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011; 9: 36-41
13. Ariyaratnam J, Subramanian V. Association between thiopurine use and nonmelanoma skin cancer in patients with inflammatory bowel disease: a meta-analysis. Am J Gastroenterol. 2014; 109: 163-169
14. Rutgeerts P, Sandborn WJ, Feagan BG., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353: 2462-2476
15. Reinisch W, Sandborn WJ, Hommes DW., et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomized controlled trial. Gut. 2011; 60: 780-787
16. Sandborn WJ, Van Assche G, Reinisch W., et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012; 142: 257-265
17. Sandborn WJ, Feagan BG, Marano C., et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014; 146: 85-95
18. Sandborn WJ, Feagan BG, Marano C., et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014; 146: 96-109
19. Arias MT, Vande Casteele N, Vermeire S., et al. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2015; 13: 531-538
20. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohns disease: a review. Am J Gastroenterol. 2009; 104: 760-767
21. Shahidi N, Fu YTN, Qian H., et al. Performance of interferon-gamma release assays in patients with inflammatory bowel disease: A systematic review and meta-analysis. Inflamm Bowel Dis. 2012; 18: 2034-2042
22. Keane J, Gerson S, Wise RP., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha neutralizing agent. N Engl J Med. 2001; 345: 1098-1104
23. Shahidi N, Bressler B. Effective tuberculosis and hepatitis B screening prior to anti-TNF-alpha therapy; are we there yet?. Dig Dis Sci. 2014; 59: 507-509
24. Berlin C, Berg EL, Briskin MJ., et al. Alpha 4 beta 7 integrin mediates lymphocyte bindings to the mucosal vascular addressin MAdCAM-1. Cell. 1993; 74: 185-195
25. Hesterberg PE, Winsor-Hines D, Briskin MJ., et al. Rapid resolution of chronic colitis in the cotton-top tamarind with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology. 1996; 111: 1373-1380
26. Langer-Gould A, Atlas SW, Green AJ., et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005; 353: 375-381
27. Van Assche G, Van Ranst M, Sciot R., et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohns disease. N Engl J Med. 2005; 353: 362-368
28. Feagan BG, Greenberg GR, Wild G., et al. Treatment of ulcerative colitis with a humanized antibody to the 4β7 integrin. N Engl J Med. 2005; 352: 2499-2507
29. Parikh A, Leach T, Wyant T., et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis. 2012; 18: 1470-1479
30. Feagan BG, Rutgeerts P, Sands BE., et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013; 369: 699-710
31. Molodecky NA, Shoon IS, Rabi DM., et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012; 142: 46-64
32. Kappelman MD, Rifas-Shiman SL, Porter C., et al. Direct health care costs of Crohns disease and ulcerative colitis in United States children and adult. Gastroenterology. 2008; 135: 1907-1913
33. Sandborn WJ, Feagan BG, Rutgeerts P., et al. Vedolizumab as induction and maintenance therapy for Crohns disease. N Engl J Med. 2013; 369: 711-721
34. Sands BE, Feagan BG, Rutgeerts P., et al. Effects of vedolizumab induction therapy for patients with Crohns disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014; 147: 618-627
35. Danese S, Fiorino G, Peyrin-Biroulet L., et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med. 2014; 160: 704-711
36. Mosli MH, MacDonald JK, Bickston SJ., et al. Vedolizumab for induction and maintenance of remission in ulcerative colitis: A Cochrane systematic review and meta-analysis. Inflamm Bowel Dis. 2015; 21: 1151-1159
37. Colombel JF, Sands BE, Hanauer SB., et al. Long-term safety of vedolizumab for the treatment of ulcerative colitis or Crohns disease. Am J Gastroenterol. 2013; 108: S502
38. Wang MC, Zhang LY, Han W., et al. PRISMA-efficacy and safety of vedolizumab for inflammatory bowel diseases. Medicine. 2014; 93: e326
39. Katz S, Pardi DS. Inflammatory bowel disease of the elderly: Frequently asked questions (FAQs). Am J Gastroenterol. 2011; 106: 1889-1897
40. Bressler B, Marshall JK, Bernstein CN., et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015; 148: 1035-1058
41. Vande Casteele N, Khanna R, Levesque BG., et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohns disease. Gut. 2015;64:1539-1545
42. Vande Casteele N, Ferrante M, Van Assche G., et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148:1320-1329
43. Rosario M, Dirks NL, Gastonguay MR., et al. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohns disease. Aliment Pharmacol Ther. 2015; 42: 188-202